Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE
In this large, observational study, enoxaparin, particularly in twice-daily regimens, was associated with significantly increased risks of bleeding and mortality compared to tinzaparin/dalteparin. These findings may help refine LMWH selection and dosing strategies in patients with cancer-associated VTE and warrant further investigation in prospective studies.
Authors
- Ren Mao (ORCID: https://orcid.org/0000-0002-5523-8185)
- Najib Dally
- Benjamin Brenner (ORCID: https://orcid.org/0000-0003-3139-085X)
- M. L. Pesce
- Joaquín Alfonso‐Megido
- Manuel Monréal (ORCID: https://orcid.org/0000-0002-0494-0767)
- Covadonga Gómez‐Cuervo (ORCID: https://orcid.org/0000-0003-2294-2229)
- Alicia Alda‐Lozano
- P. Prandoni
- Jacinto Hernández-Borge
Institutions
- Université de Bretagne Occidentale (FR)
- Technion – Israel Institute of Technology (IL)
- Rambam Health Care Campus (IL)
- Rebecca Sieff Hospital (IL)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Reina Sofía (ES)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Centro de Implantología Cirugía Oral y Maxilofacial (ES)
- Hospital General de Elda (ES)
- Hospital Valle del Nalón (ES)
- French Clinical Research Infrastructure Network (FR)
- Universidad Católica de Murcia (ES)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1016/j.rpth.2025.103244
- Citations
- 1
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.87